Marc van Dijk
Chief Tech/Sci/R&D Officer bij MINK THERAPEUTICS, INC.
Vermogen: 24 846 $ op 31-03-2024
Profiel
Marc van Dijk is currently the Chief Scientific Officer at MiNK Therapeutics, Inc. He previously held positions as the Director of Applied Research & Development at Fujirebio Europe NV, Chief Scientific Officer at Medarex, Inc., Chief Technology Officer at Agenus, Inc., Scientist at the University of California, Berkeley, Chief Technology Officer at 4-Antibody AG, Vice President of Antibody Technology at Genmab, Inc., and Principal at the University Medical Center of Utrecht.
Dr. van Dijk obtained his doctorate degree from the University of Utrecht in 1992.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
MINK THERAPEUTICS, INC.
0.08% | 16-01-2024 | 27 363 ( 0.08% ) | 24 846 $ | 31-03-2024 |
Actieve functies van Marc van Dijk
Bedrijven | Functie | Begin |
---|---|---|
MINK THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01-03-2020 |
Eerdere bekende functies van Marc van Dijk
Bedrijven | Functie | Einde |
---|---|---|
Fujirebio Europe NV
Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | Chief Tech/Sci/R&D Officer | 01-11-2008 |
Genmab, Inc.
Genmab, Inc. Miscellaneous Commercial ServicesCommercial Services Genmab, Inc. creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. It also offers products for cancer and autoimmune disorders. The company is headquartered in Princeton, NJ. | Chief Tech/Sci/R&D Officer | 01-01-2005 |
AGENUS INC. | Chief Tech/Sci/R&D Officer | - |
Medarex, Inc.
Medarex, Inc. Miscellaneous Commercial ServicesCommercial Services Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey. | Chief Tech/Sci/R&D Officer | - |
University Medical Center of Utrecht | Corporate Officer/Principal | - |
Opleiding van Marc van Dijk
University of Utrecht | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
AGENUS INC. | Health Technology |
MINK THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 4 |
---|---|
Medarex, Inc.
Medarex, Inc. Miscellaneous Commercial ServicesCommercial Services Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey. | Commercial Services |
Fujirebio Europe NV
Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | Health Technology |
4-Antibody AG
4-Antibody AG Pharmaceuticals: MajorHealth Technology 4-Antibody AG was discovers and develops drugs. The company was founded in 2002 and headquartered in Basel, Switzerland. | Health Technology |
Genmab, Inc.
Genmab, Inc. Miscellaneous Commercial ServicesCommercial Services Genmab, Inc. creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. It also offers products for cancer and autoimmune disorders. The company is headquartered in Princeton, NJ. | Commercial Services |